Biosite Agrees To Inverness Merger Talks While Beckman Waits At The Altar
This article was originally published in The Gray Sheet
Executive Summary
Heart test maker Biosite has agreed to merger talks with Inverness Medical Innovations despite its previous agreement to be acquired by Beckman Coulter for $1.55 billion
You may also be interested in...
Beckman Coulter Ponders Inverness’ “Superior” Bid For Biosite
Beckman Coulter has until May 2 to engage in a bidding war with Inverness Medical Innovations for cardiac diagnostic maker Biosite
Beckman Coulter Ponders Inverness’ “Superior” Bid For Biosite
Beckman Coulter has until May 2 to engage in a bidding war with Inverness Medical Innovations for cardiac diagnostic maker Biosite
Beckman Coulter Buys Cardiac Test Developer Biosite For $1.55 Billion
In a $1.55 billion acquisition plan announced March 25, Beckman Coulter looks to combine its strength as a leading manufacturer of lab instruments with the complementary expertise of diagnostic test developer Biosite